Patents by Inventor John A. Lewicki

John A. Lewicki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF
    Publication number: 20170198031
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Application
    Filed: October 20, 2016
    Publication date: July 13, 2017
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Timothy Charles HOEY, Edward Thein Htun van der HORST, Aaron Ken SATO, Yuan Ching LIU, Maureen Fitch BRUHNS, John A. LEWICKI
  • Antibodies to a non-ligand binding region of at least two NOTCH receptors
    Patent number: 9676865
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: June 13, 2017
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: John A. Lewicki, Austin L. Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
  • Method of treating cancer by administering a monoclonal antibody that binds human NOTCH2 and NOTCH3
    Patent number: 9505832
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: November 29, 2016
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER
    Publication number: 20160053016
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
    Type: Application
    Filed: June 18, 2014
    Publication date: February 25, 2016
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: John A. LEWICKI, Austin L. Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
  • NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF
    Publication number: 20150197563
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Application
    Filed: January 20, 2015
    Publication date: July 16, 2015
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • Monoclonal antibody that binds human notch2 and notch3
    Patent number: 8980260
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 17, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • Polynucleotides encoding Notch receptor antibodies
    Patent number: 8945873
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: February 3, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • Method of treating cancer using antibodies to a non-ligand binding region of NOTCH1
    Patent number: 8784811
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: July 22, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: John A. Lewicki, Austin Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
  • METHODS FOR TREATING CANCER WITH NOTCH2/3 ANTIBODIES
    Publication number: 20130323266
    Abstract: The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of a Notch2/3 antibody.
    Type: Application
    Filed: May 16, 2013
    Publication date: December 5, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Timothy Charles HOEY, John A. Lewicki, Wan-Ching Yen, Jakob Dupont
  • NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF
    Publication number: 20130296536
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Application
    Filed: March 14, 2013
    Publication date: November 7, 2013
    Inventors: Austin L. GURNEY, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF
    Publication number: 20130260455
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Application
    Filed: March 1, 2013
    Publication date: October 3, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER
    Publication number: 20130251705
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
    Type: Application
    Filed: February 22, 2013
    Publication date: September 26, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: John A. LEWICKI, Austin Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
  • Methods of treatment by administering antibodies to notch receptors
    Patent number: 8425903
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: April 23, 2013
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • Antibodies to the NOTCH1 receptor
    Patent number: 8404237
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: March 26, 2013
    Assignee: OncoMed Pharamaceuticals, Inc.
    Inventors: John A. Lewicki, Austin Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
  • ANTIBODIES TO THE NOTCH1 RECEPTOR
    Publication number: 20130030155
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
    Type: Application
    Filed: May 15, 2012
    Publication date: January 31, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: John A. LEWICKI, Austin Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
  • Notch-Binding Agents and Antagonists and Methods of Use Thereof
    Publication number: 20120288496
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Application
    Filed: May 15, 2012
    Publication date: November 15, 2012
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • Antibodies to notch receptors
    Patent number: 8226943
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: July 24, 2012
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • Method of treating cancer using antibodies to a non-ligand binding region of NOTCH2
    Patent number: 8206713
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: June 26, 2012
    Assignee: Oncomed Pharmaceuticals, Inc.
    Inventors: John A. Lewicki, Austin Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
  • Compositions and Methods for Diagnosing and Treating Cancer
    Publication number: 20110195065
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
    Type: Application
    Filed: January 20, 2011
    Publication date: August 11, 2011
    Inventors: John A. LEWICKI, Austin GURNEY, Timothy HOEY, Wan-Ching YEN, Sanjeev SATYAL
  • COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER
    Publication number: 20110183866
    Abstract: The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles and signatures associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of solid tumor stem cells. More particularly, the present invention identifies two profiles of cancer stem cells useful for the diagnosis, characterization, and treatment of cancer and cancer metastases. The invention also provides a variety of reagents such as stem cell gene signatures for use in the diagnosis and management of cancer.
    Type: Application
    Filed: March 31, 2011
    Publication date: July 28, 2011
    Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, ONCOMED PHARMACEUTICALS, INC.
    Inventors: Michael F. Clarke, Xinhao Wang, John A. Lewicki, Austin L. Gurney